KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $29.40 Average PT from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have earned a consensus rating of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $29.40.

KALV has been the subject of a number of research reports. Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Citizens Jmp reduced their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Tuesday, November 11th. TD Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th.

KalVista Pharmaceuticals Trading Up 6.6%

Shares of KALV opened at $17.30 on Friday. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The company has a market cap of $874.52 million, a price-to-earnings ratio of -4.38 and a beta of -0.35. The stock has a fifty day moving average price of $15.61 and a two-hundred day moving average price of $14.16. KalVista Pharmaceuticals has a 52-week low of $9.23 and a 52-week high of $19.00.

Insider Activity at KalVista Pharmaceuticals

In related news, insider Nicole Sweeny sold 3,975 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $61,890.75. Following the completion of the transaction, the insider owned 47,003 shares in the company, valued at $731,836.71. The trade was a 7.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Paul K. Audhya sold 5,354 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $83,361.78. Following the transaction, the insider directly owned 138,983 shares in the company, valued at approximately $2,163,965.31. This represents a 3.71% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 26,685 shares of company stock worth $414,667. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Emerald Advisers LLC increased its position in KalVista Pharmaceuticals by 30.2% in the third quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock worth $16,458,000 after purchasing an additional 313,205 shares during the period. Blue Owl Capital Holdings LP acquired a new position in KalVista Pharmaceuticals during the 3rd quarter valued at about $1,522,000. Stonepine Capital Management LLC boosted its stake in shares of KalVista Pharmaceuticals by 364.0% in the 2nd quarter. Stonepine Capital Management LLC now owns 100,000 shares of the specialty pharmaceutical company’s stock valued at $1,130,000 after purchasing an additional 78,450 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its stake in shares of KalVista Pharmaceuticals by 19.4% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 917,975 shares of the specialty pharmaceutical company’s stock valued at $11,181,000 after purchasing an additional 149,003 shares during the last quarter. Finally, F m Investments LLC grew its position in shares of KalVista Pharmaceuticals by 263.8% during the 2nd quarter. F m Investments LLC now owns 182,262 shares of the specialty pharmaceutical company’s stock worth $2,060,000 after buying an additional 132,165 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.